TY - JOUR
T1 - Perceived safety, usability, and acceptability of microarray patches for vaccination among key populations
T2 - A mixed methods study
AU - Berger, Matthew N.
AU - Davies, Cristyn
AU - Mathieu, Erin
AU - Harmer-Ross, Josh
AU - Shaban, Ramon Z.
AU - Cassidy-Matthews, Chenoa
AU - Wilson, Brittany
AU - Bag, Shopna
AU - Skinner, S. Rachel
N1 - Publisher Copyright:
© 2025
PY - 2025/8/13
Y1 - 2025/8/13
N2 - Introduction: Vaccination is crucial for public and population health. Microarray patches (MAPs) could enhance vaccine uptake through reduced pain, no needles, improved thermostability and self or lay administration, but there is limited evidence. We aimed to investigate the perceptions of the general public and healthcare professionals (HCPs) aged 18 years and older about MAP vaccination. Methods: This mixed-methods study was part of a project to validate a scale measuring MAP vaccination's safety, usability, and acceptability. Online surveys and semi-structured interviews were conducted in Australia, Canada, United Kingdom, and New Zealand. 7-point Likert scale items were scaled from “strongly disagree” to “strongly agree” and analysed using descriptive statistics (e.g., means and confidence intervals (CI)). Interviews were transcribed verbatim, coded, and analysed using thematic analysis. Results: In the survey group, 403 general public and 184 HCPs responded. We interviewed 27 participants (12 general public and 15 HCPs). The general public and HCPs perceived MAPs as safe and efficacious, with means of 5.00 (95 % CI: 4.85–5.14) and 4.92 (95 % CI: 4.71–5.12) respectively. The general public (mean = 5.58, 95 % CI: 5.46–5.70) and HCPs (mean = 5.75, 95 % CI: 5.59–5.92) perceived MAPs as usable. Lastly, the general public (mean = 5.49, 95 % CI: 5.37–5.61) and HCPs (mean = 5.30, 95 % CI: 5.12–5.50) perceived MAPs as acceptable. Participants widely perceived MAPs as safe and easy to use due to their ‘straightforward’ instructions, including for self-administration. All participants regarded MAPs as advantageous for children and needle-phobic individuals. Some HCPs were concerned about possible adverse events at home (i.e., anaphylaxis), but were interested in incorporating MAPs in their clinical practice. Conclusion: Microarray patches (MAPs) MAPs are viewed by the general public and HCPs as safe, user-friendly, and well-received as alternatives to needle and syringe vaccination for greater acceptability among consumers. MAPS may also improve access to vaccination in priority populations and areas with limited resources.
AB - Introduction: Vaccination is crucial for public and population health. Microarray patches (MAPs) could enhance vaccine uptake through reduced pain, no needles, improved thermostability and self or lay administration, but there is limited evidence. We aimed to investigate the perceptions of the general public and healthcare professionals (HCPs) aged 18 years and older about MAP vaccination. Methods: This mixed-methods study was part of a project to validate a scale measuring MAP vaccination's safety, usability, and acceptability. Online surveys and semi-structured interviews were conducted in Australia, Canada, United Kingdom, and New Zealand. 7-point Likert scale items were scaled from “strongly disagree” to “strongly agree” and analysed using descriptive statistics (e.g., means and confidence intervals (CI)). Interviews were transcribed verbatim, coded, and analysed using thematic analysis. Results: In the survey group, 403 general public and 184 HCPs responded. We interviewed 27 participants (12 general public and 15 HCPs). The general public and HCPs perceived MAPs as safe and efficacious, with means of 5.00 (95 % CI: 4.85–5.14) and 4.92 (95 % CI: 4.71–5.12) respectively. The general public (mean = 5.58, 95 % CI: 5.46–5.70) and HCPs (mean = 5.75, 95 % CI: 5.59–5.92) perceived MAPs as usable. Lastly, the general public (mean = 5.49, 95 % CI: 5.37–5.61) and HCPs (mean = 5.30, 95 % CI: 5.12–5.50) perceived MAPs as acceptable. Participants widely perceived MAPs as safe and easy to use due to their ‘straightforward’ instructions, including for self-administration. All participants regarded MAPs as advantageous for children and needle-phobic individuals. Some HCPs were concerned about possible adverse events at home (i.e., anaphylaxis), but were interested in incorporating MAPs in their clinical practice. Conclusion: Microarray patches (MAPs) MAPs are viewed by the general public and HCPs as safe, user-friendly, and well-received as alternatives to needle and syringe vaccination for greater acceptability among consumers. MAPS may also improve access to vaccination in priority populations and areas with limited resources.
KW - Acceptability
KW - Microarray patch
KW - Safety
KW - Usability
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=105007416173&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2025.127387
DO - 10.1016/j.vaccine.2025.127387
M3 - Article
AN - SCOPUS:105007416173
SN - 0264-410X
VL - 61
JO - Vaccine
JF - Vaccine
M1 - 127387
ER -